focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Regulatory News (HLN)

Share Price Information for Haleon (HLN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 332.40
Bid: 331.30
Ask: 331.40
Change: 1.10 (0.33%)
Spread: 0.10 (0.03%)
Open: 330.50
High: 332.40
Low: 328.80
Prev. Close: 331.30
HLN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Haleon to sell ChapStick

25 Jan 2024 07:00

RNS Number : 8353A
Haleon PLC
25 January 2024
 

 

Haleon to sell ChapStick

25 January 2024: Haleon plc, a global leader in consumer health, has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands Company, a portfolio company of Yellow Wood Partners. Under the terms of the transaction, Haleon will receive pre-tax cash proceeds of approximately $430 million, as well as a passive minority interest in the Suave Brands Company. At the time of entering into the binding agreement, this interest was valued at approximately $80 million. Cash proceeds from the sale will be used to pay down debt, underpinning our confidence to de-lever to net debt/Adjusted EBITDA of below 3x during 2024.ChapStick generated £112 million in revenue for the FY ended 31 December 2023.The sale, subject to the satisfaction of customary closing conditions, is expected to close in the second quarter of 2024.Further detail on the transaction and its impact will be provided within our FY 2023 Results announcement on 29 February 2024. Brian McNamara, Chief Executive Officer, Haleon, said: "Today's announcement is consistent with Haleon being proactive in managing our portfolio, and being rigorous and disciplined where there are opportunities for divestment. While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon. Selling the brand allows us to simplify our business and pay down debt more quickly. We're confident the brand will continue to thrive under its new ownership." Ends

---

 

Enquiries

 

Investors

 

Media

 

Sonya Ghobrial

+44 7392 784784

Nidaa Lone

+44 7841 400607

Rakesh Patel

+44 7552 484646

Emma White

+44 7792 750133 

 

About ChapStick

ChapStick, the lip expert, makes it a priority to help people care for their lips all year round. Originally created in the early 1880s, ChapStick is known today as America's favourite lip balm. As part of Haleon, ChapStick offers a variety of products and fun flavours that promote happier and healthier lips. For more information, please visit www.chapstick.com.

 

About Haleon

 

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com.  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISFFFVLLVISFIS
Date   Source Headline
8th May 20245:15 pmRNSResults of Haleon 2024 Annual General Meeting
7th May 20249:30 amRNSEMTN programme: publication of base prospectus
1st May 202411:10 amRNSDirectorate Change
1st May 20247:00 amRNSHaleon 2024 Q1 Trading Statement
24th Apr 20247:00 amRNSAppointment of Dawn Allen as CFO
12th Apr 202412:00 pmRNSNotice of Annual General Meeting (AGM)
3rd Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 20249:15 amRNSTotal Voting Rights and Capital
22nd Mar 202411:30 amRNSHolding(s) in Company
21st Mar 20246:00 pmRNSHaleon
21st Mar 20244:38 pmRNSTotal Voting Rights and Capital
21st Mar 20244:05 pmRNSClosing of Secondary Global Offering by Pfizer
20th Mar 20248:39 amRNSFinal prospectus supplement filed with the SEC
19th Mar 20247:00 amRNSPricing and upsize of Secondary Global Offering
18th Mar 202411:00 amRNSPreliminary prospectus supplement filed with SEC
18th Mar 20247:00 amRNSProposed Secondary Global Offering by Pfizer Inc.
15th Mar 20243:00 pmRNSPublication of Annual Report and Form 20-F 2023
14th Mar 20244:20 pmRNSDirector/PDMR Shareholding
12th Mar 20243:30 pmRNSDirector/PDMR Shareholding
5th Mar 20242:30 pmRNSDirector/PDMR Shareholding
29th Feb 20247:00 amRNSHaleon Preliminary 2023 Full Year Results
2nd Feb 20242:15 pmRNSDirector Declaration
25th Jan 20247:00 amRNSHaleon to sell ChapStick
18th Jan 20245:00 pmRNSHolding(s) in Company
17th Jan 20246:00 pmRNSHaleon
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
19th Dec 20231:00 pmRNSDirector/PDMR Shareholding
13th Dec 202310:30 amRNSDirector/PDMR Shareholding
10th Nov 20231:00 pmRNSDirector/PDMR Shareholding
2nd Nov 20237:00 amRNSHaleon 2023 Q3 Trading Statement
13th Oct 20233:30 pmRNSDirector/PDMR Shareholding
11th Oct 20233:00 pmRNSDirector/PDMR Shareholding
10th Oct 202311:00 amRNSHolding(s) in Company
6th Oct 20236:00 pmRNSHaleon
6th Oct 20232:30 pmRNSDirector/PDMR Shareholding
28th Sep 202311:00 amRNSDirector Declaration
13th Sep 20239:30 amRNSDirector/PDMR Shareholding
10th Aug 20231:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20237:00 amRNSHaleon Half Year Results 2023
13th Jul 202311:00 amRNSDirector/PDMR Shareholding
12th Jun 20231:00 pmRNSDirector/PDMR Shareholding
16th May 20232:00 pmRNSHolding(s) in Company
16th May 20232:00 pmRNSHolding(s) in Company
12th May 20235:30 pmRNSHaleon
12th May 20234:30 pmRNSDirector/PDMR Shareholding
12th May 20239:30 amRNSEMTN programme publication of base prospectus
9th May 20235:00 pmRNSDirector/PDMR Shareholding
3rd May 20237:00 amRNS2023 Q1 Trading Statement
2nd May 20234:00 pmRNSDirector/PDMR Shareholding
20th Apr 20235:30 pmRNSResults of Haleon 2023 Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.